GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Abeona Therapeutics ABEO · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.54

-39.09%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Abeona Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Abeona Therapeutics is based in Cleveland, Ohio and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ABEO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $5.8m and net income of $71.2m. At that date it held total assets of $219.6m and shareholders' equity of $159.2m. By business, License [Member] brought in 58.4% of revenue, followed by Product [Member] at 41.6%.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
19 Sept 1980
Employees
226
Head office
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH, 44103
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Michael AmorosoChairman of the Board, since 2020$261,048
  • Dr. Vishwas SeshadriPresident, Chief Executive Officer, Director, since 2021$3.5m
  • Mr. Joseph VazzanoChief Financial Officer$1.6m
  • Dr. Brendan O MalleyGeneral Counsel$1.3m
  • Dr. Leila AllandIndependent Director$249,798
  • Mr. Mark AlvinoIndependent Director$246,048
  • Ms. Faith CharlesIndependent Director$246,048
  • Dr. Eric CrombezIndependent Director$74,230
  • Ms. Christine SilversteinIndependent Director, since 2019$234,880
  • Mr. Donald WuchterlIndependent Director$246,048
  • Dr. Bernhardt ZeiherIndependent Director$74,779

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
32
Environment
35
Social
38
Governance
25
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Abeona Therapeutics develops gene therapies for rare diseases like Sanfilippo syndrome type A.
  • The company has a diverse pipeline including ABO-102 and ABO-101 for genetic disorders.
  • Abeona's plasma-based protein therapy SDF Alpha targets inherited COPD using ethanol-free process.

Weaknesses

  • Abeona employs only 88 full-time employees despite being a clinical stage company.
  • The company's lead programs are still in clinical development stages.
  • Abeona's business is focused on rare diseases with limited market size.

Opportunities

  • Abeona's ABO-201 for juvenile Batten disease could address unmet medical needs.
  • The firm's CRISPR/Cas9-based gene editing approach offers innovative treatment options.
  • Expanding ABO-302 for rare blood diseases may open new market segments.

Threats

  • Competition from other biotech firms developing similar gene therapies.
  • Regulatory hurdles may delay approval of Abeona's clinical stage therapies.
  • Rare disease treatments face high development costs and uncertain reimbursement.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.